Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

KRT17 antibody

KRT17 Reactivity: Human, Rat, Cow, Pig, Goat WB, IHC, IF, FACS, StM Host: Mouse Monoclonal SPM560 unconjugated
Catalog No. ABIN6939923
  • Target See all KRT17 Antibodies
    KRT17 (Keratin 17 (KRT17))
    Reactivity
    • 122
    • 47
    • 30
    • 17
    • 12
    • 10
    • 6
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    Human, Rat, Cow, Pig, Goat
    Host
    • 97
    • 35
    • 1
    Mouse
    Clonality
    • 89
    • 44
    Monoclonal
    Conjugate
    • 56
    • 15
    • 9
    • 6
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This KRT17 antibody is un-conjugated
    Application
    • 101
    • 46
    • 38
    • 29
    • 27
    • 26
    • 19
    • 18
    • 16
    • 15
    • 8
    • 3
    • 3
    • 2
    • 2
    • 2
    Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS), Staining Methods (StM)
    Purification
    Purified by Protein A/G
    Immunogen
    The cytoskeletal fraction of rat colon epithelium
    Clone
    SPM560
    Isotype
    IgG2b kappa
    Top Product
    Discover our top product KRT17 Primary Antibody
  • Application Notes

    Positive Control: HeLa cells, Skin.

    Known Application: Flow Cytometry (0.5-1 μg/million cells), Immunofluorescence (1-2 μg/mL), Western Blot (0.5-1.0 μg/mL), Immunohistochemistry (Formalin-fixed) (0.5-1 μg/mL for 30 min at RT)(Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.

    Restrictions
    For Research Use only
  • Concentration
    200 μg/mL
    Buffer
    10 mM PBS with 0.05 % BSA & 0.05 % azide.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-80 °C
    Storage Comment
    Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
    Expiry Date
    24 months
  • Target
    KRT17 (Keratin 17 (KRT17))
    Alternative Name
    KRT17 (KRT17 Products)
    Synonyms
    K17 antibody, Krt1-17 antibody, PC antibody, PC2 antibody, PCHC1 antibody, Ka17 antibody, KRT17 antibody, krt16 antibody, si:dkeyp-113d7.7 antibody, KRT14 antibody, keratin 17 antibody, keratin 17 L homeolog antibody, keratin 17, type I antibody, keratin, type I cytoskeletal 17 antibody, Krt17 antibody, KRT17 antibody, krt17 antibody, krt17.L antibody, LOC100737113 antibody, LOC102177275 antibody
    Background
    Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFP's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20 % of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.
    Molecular Weight
    46kDa
    Gene ID
    3872
    UniProt
    Q04695
You are here:
Support